Adipotide dosage and protocol
Adipotide is a synthetic peptidomimetic that targets prohibitin on blood vessels within white adipose tissue and delivers a pro-apoptotic sequence to destroy those vessels, resulting in targeted fat mass reduction as fat cells lose their blood supply. Preclinical studies showed notable weight loss in obese rodents and primates.
- Vial size: 10 mg
- Reconstitution: 3 mL bacteriostatic water
- Concentration: 3.33 mg/mL
- Administration: subcutaneous
Research areas
- Fat Loss
- Weight Management
- Body Recomposition
- Metabolic Health
Quick start
- Reconstitute: Add 3.0 mL bacteriostatic water to the 10 mg vial → 3.33 mg/mL
- Typical dose: 250–1,000 mcg once daily (SC), titrated over 8 weeks
- Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33 mcg; 250 mcg ≈ 7.5 units, 500 mcg = 15 units, 1,000 mcg = 30 units on a U-100 syringe
- Storage: Lyophilized at −20°C; refrigerate at 2–8°C after mixing and avoid freeze-thaw cycles
Dosing protocol
| Phase | Dose | Frequency | Volume |
|---|---|---|---|
| Weeks 1–2 | 250mcg | Once daily | 0.08mL |
| Weeks 3–4 | 500mcg | Once daily | 0.15mL |
| Weeks 5–6 | 750mcg | Once daily | 0.23mL |
| Weeks 7–8 | 1000mcg | Once daily | 0.30mL |
How it works
Adipotide (also known as FTPP or prohibitin-targeting peptide 1) is a synthetic peptidomimetic with two functional parts. The first is a targeting motif that binds prohibitin, a protein displayed on the surface of endothelial cells lining blood vessels in white adipose tissue, together with its partner annexin A2. The second is a pro-apoptotic sequence, D(KLAKLAK)2, that is internalized by those endothelial cells and disrupts mitochondrial membranes, triggering cell death. By selectively destroying the vasculature that supplies white fat, adipotide deprives adipocytes of blood flow; the fat cells are then resorbed. In obese mouse models and later in obese rhesus monkeys, treatment produced meaningful reductions in body weight and fat mass, along with improved insulin sensitivity. Monkeys also showed reduced food intake during treatment, so some of the weight loss may reflect appetite changes. The main safety signal was kidney toxicity: dose-dependent, largely reversible renal tubular injury was seen in primates. A phase 1 trial in men with prostate cancer explored the compound but development did not proceed to approval. Adipotide is not approved for any use, and the narrow gap between effective and nephrotoxic doses is a central concern.
Reconstitution steps
- Draw 3.0mL bacteriostatic water with a sterile syringe
- Inject slowly down the vial wall; avoid foaming
- Gently swirl/roll until dissolved (do not shake)
- Label and refrigerate at 2–8°C, protected from light
Storage
Store lyophilized at -20°C (-4°F). After reconstitution, refrigerate at 2–8°C and avoid freeze-thaw cycles.
Important notes
- Research use only
- Clinical development discontinued due to reversible kidney toxicity at higher doses — use conservative doses
- Gradual dose escalation is essential to mitigate renal side effects
- Targets prohibitin on adipose tissue vasculature — mechanism distinct from other fat-loss peptides
- Rotate injection sites systematically to reduce local irritation
- Monitor kidney function markers during use
Supplies
- Bacteriostatic water
- Insulin syringes (U-100)
- Alcohol swabs